

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2004/013175

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61K38/17 C12N5/10 A01K67/027 G01N33/50 C12Q1/68 A61P3/00		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 A61K C12N C12Q G01N A61P		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, BIOSIS, EMBASE, WPI Data, PAJ, PASCAL		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, Y	WO 2004/087194 A (DEVELOGEN AKTIENGESELLSCHAFT FUER ENTWICKLUNGSBIOLOGISCHE FORSCHUNG; O) 14 October 2004 (2004-10-14) the whole document	1-41
P, X	CRAS-MÉNEUR C ET AL: "An expression profile of human pancreatic islet mRNAs by Serial Analysis of Gene Expression (SAGE)." DIABETOLOGIA. FEB 2004, vol. 47, no. 2, February 2004 (2004-02), pages 284-299, XP002330420 ISSN: 0012-186X the whole document	1-41
----- -/--		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents : <div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>*A* document defining the general state of the art which is not considered to be of particular relevance</p> <p>*E* earlier document but published on or after the international filing date</p> <p>*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>*O* document referring to an oral disclosure, use, exhibition or other means</p> <p>*P* document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>*G* document member of the same patent family</p> </div> </div>		
Date of the actual completion of the international search	Date of mailing of the international search report	
3 June 2005	25. 08. 2005	
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer Fayos, C	

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP2004/013175

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
T	DATABASE GENBANK 'Online! 10 April 2005 (2005-04-10), XP002330263 retrieved from GENBANK Database accession no. NM_026522 abstract	1-41
X	----- OSHIMA KENJI ET AL: "Secretion of a peripheral membrane protein, MFG-E8, as a complex with membrane vesicles. A POSSIBLE ROLE IN MEMBRANE SECRETION" EUROPEAN JOURNAL OF BIOCHEMISTRY, BERLIN, DE, vol. 269, no. 4, February 2002 (2002-02), pages 1209-1218, XP002233407 ISSN: 0014-2956 cited in the application abstract page 1210, column 1, paragraph 3 - column 2, paragraph 1	27, 41
Y	the whole document	1-41
X	----- US 5 279 966 A (JESSELL ET AL) 18 January 1994 (1994-01-18)	1-21, 25-33
Y	the whole document	1-41
X	----- US 2002/144296 A1 (WHEELER MATTHEW B ET AL) 3 October 2002 (2002-10-03) NM_005928 page 10, paragraph 90	25-27, 41
X	----- EP 1 149 844 A (RIKEN) 31 October 2001 (2001-10-31)	1-21, 25-33
Y	claims 1-10	1-41
Y	----- KAWAMURA K ET AL: "A new family of growth factors produced by the fat body and active on Drosophila imaginal disc cells." DEVELOPMENT (CAMBRIDGE, ENGLAND) JAN 1999, vol. 126, no. 2, January 1999 (1999-01), pages 211-219, XP002330421 ISSN: 0950-1991 cited in the application the whole document	1-41

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP2004/013175

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-41 (partially)

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-41 (partially)

A pharmaceutical composition comprising SF1, its use for the treatment of pancreatic diseases, obesity, metabolic syndrome and / or other metabolic diseases or dysfunctions, its use in identification / screening methods, a non human transgenic animal or recombinant host cell exhibiting a modified expression of SF1.

2. claims: 1-41 (partially)

A pharmaceutical composition comprising SF2, its use for the treatment of pancreatic diseases, obesity, metabolic syndrome and / or other metabolic diseases or dysfunctions, its use in identification / screening methods, a non human transgenic animal or recombinant host cell exhibiting a modified expression of SF2.

3. claims: 1-41 (partially)

A pharmaceutical composition comprising SF3, its use for the treatment of pancreatic diseases, obesity, metabolic syndrome and / or other metabolic diseases or dysfunctions, its use in identification / screening methods, a non human transgenic animal or recombinant host cell exhibiting a modified expression of SF3.

4. claims: 1-41 (partially)

A pharmaceutical composition comprising SF4, its use for the treatment of pancreatic diseases, obesity, metabolic syndrome and / or other metabolic diseases or dysfunctions, its use in identification / screening methods, a non human transgenic animal or recombinant host cell exhibiting a modified expression of SF4.

5. claims: 1-41 (partially)

A pharmaceutical composition comprising SF5, its use for the treatment of pancreatic diseases, obesity, metabolic syndrome and / or other metabolic diseases or dysfunctions, its use in identification / screening methods, a non human transgenic animal or recombinant host cell exhibiting a modified expression of SF5.

6. claims: 1-41 (partially)

FURTHER INFORMATION CONTINUED FROM PCT/ISA 210

A pharmaceutical composition comprising SF6, its use for the treatment of pancreatic diseases, obesity, metabolic syndrome and / or other metabolic diseases or dysfunctions, its use in identification / screening methods, a non human transgenic animal or recombinant host cell exhibiting a modified expression of SF6.

7. claims: 1-41(partially)

A pharmaceutical composition comprising SF7, its use for the treatment of pancreatic diseases, obesity, metabolic syndrome and / or other metabolic diseases or dysfunctions, its use in identification / screening methods, a non human transgenic animal or recombinant host cell exhibiting a modified expression of SF7.

8. claims: 1-41 (partially)

A pharmaceutical composition comprising SF8, its use for the treatment of pancreatic diseases, obesity, metabolic syndrome and / or other metabolic diseases or dysfunctions, its use in identification / screening methods, a non human transgenic animal or recombinant host cell exhibiting a modified expression of SF8.

9. claims: 1-24 (partially)

A pharmaceutical composition comprising an effector / modulator of any of SF1-SF8, its use for the treatment of pancreatic diseases, obesity, metabolic syndrome and / or other metabolic diseases or dysfunctions.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP2004/013175

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 2004087194	A	14-10-2004	WO 2004087194 A2	14-10-2004
US 5279966	A	18-01-1994	AU 713198 B2	25-11-1999
			AU 1269897 A	15-05-1997
			AU 677185 B2	17-04-1997
			AU 3945593 A	08-11-1993
			CA 2133443 A1	14-10-1993
			EP 0670895 A1	13-09-1995
			JP 7508402 T	21-09-1995
			WO 9320196 A1	14-10-1993
			US 5750502 A	12-05-1998
			ZA 9302362 A	15-06-1994
US 2002144296	A1	03-10-2002	US 2004064841 A1	01-04-2004
			AU 8494801 A	25-02-2002
			WO 0214473 A2	21-02-2002
EP 1149844	A	31-10-2001	JP 2001292778 A	23-10-2001
			CA 2341786 A1	11-10-2001
			EP 1149844 A2	31-10-2001
			US 2003114657 A1	19-06-2003